Clinical studies have shown that CD8 + T cells bind, via their TCRs, to tumor-specific intracellular targets that elicit deep and durable responses in solid tumors and without normal tissue toxicity.

"If we can see exhausted T cells inside a tumor, we could potentially activate those T cells with a checkpoint inhibitor or other immunotherapies," Ding said. "But if we don't see them, we will ...

"It raises the prospect of a 'one-size-fits-all' cancer treatment, a single type of T-cell that could be capable of destroying many different types of cancers across the population." T-cells have ...

Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like ...